Aquinox Pharmaceuticals Inc (NASDAQ:AQXP)’s share price reached a new 52-week low during trading on Monday . The company traded as low as $10.14 and last traded at $10.57, with a volume of 95500 shares. The stock had previously closed at $10.60.

A number of equities analysts recently commented on the stock. Canaccord Genuity set a $22.00 price target on shares of Aquinox Pharmaceuticals and gave the stock a “buy” rating in a research report on Monday. Needham & Company LLC reiterated a “buy” rating and set a $25.00 price objective on shares of Aquinox Pharmaceuticals in a research note on Thursday, November 9th. Cantor Fitzgerald reiterated a “buy” rating and set a $28.00 price objective on shares of Aquinox Pharmaceuticals in a research note on Thursday, November 9th. Zacks Investment Research downgraded shares of Aquinox Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Tuesday, October 10th. Finally, ValuEngine downgraded shares of Aquinox Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Friday, September 15th. Two analysts have rated the stock with a sell rating, one has issued a hold rating and three have issued a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and an average target price of $22.50.

A number of institutional investors have recently made changes to their positions in AQXP. Nexthera Capital LP acquired a new stake in Aquinox Pharmaceuticals during the second quarter worth about $1,276,000. Sphera Funds Management LTD. acquired a new stake in Aquinox Pharmaceuticals during the second quarter worth about $874,000. University of Notre Dame DU Lac grew its stake in Aquinox Pharmaceuticals by 11.1% during the third quarter. University of Notre Dame DU Lac now owns 190,283 shares of the company’s stock worth $2,700,000 after buying an additional 19,066 shares in the last quarter. Vanguard Group Inc. grew its stake in Aquinox Pharmaceuticals by 6.6% during the second quarter. Vanguard Group Inc. now owns 282,483 shares of the company’s stock worth $3,974,000 after buying an additional 17,455 shares in the last quarter. Finally, Citadel Advisors LLC acquired a new stake in Aquinox Pharmaceuticals during the third quarter worth about $194,000. Hedge funds and other institutional investors own 96.25% of the company’s stock.

ILLEGAL ACTIVITY WARNING: This news story was posted by Watch List News and is the property of of Watch List News. If you are accessing this news story on another website, it was stolen and republished in violation of U.S. & international copyright laws. The correct version of this news story can be read at https://www.watchlistnews.com/aquinox-pharmaceuticals-aqxp-reaches-new-12-month-low-at-10-14/1760770.html.

Aquinox Pharmaceuticals Company Profile

Aquinox Pharmaceuticals, Inc is a clinical-stage pharmaceutical company discovering and developing targeted therapeutics in disease areas of inflammation and immuno-oncology. The Company’s primary focus is anti-inflammatory product candidates targeting the Src Homology 2 (SH2)-containing inositol-5-phosphatase 1 (SHIP1) enzyme, which is a regulator of a cellular signaling pathway in immune cells, known as the phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K) pathway.

Receive News & Ratings for Aquinox Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aquinox Pharmaceuticals and related companies with Analyst Ratings Network's FREE daily email newsletter.